Non-pharmacological management options for MAFLD: a practical guide (2023)
- Authors:
- Autor USP: OLIVEIRA, CLAUDIA PINTO MARQUES SOUZA DE - FM
- Unidade: FM
- DOI: 10.1177/20420188231160394
- Subjects: CONSUMO DE ALIMENTOS; FÍGADO GORDUROSO; MODO DE VIDA
- Language: Inglês
- Imprenta:
- Source:
- Título: Therapeutic advances in endocrinology and metabolism
- ISSN: 2042-0188
- Volume/Número/Paginação/Ano: v. 14, article ID 20420188231160300, 17p, 2023
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc
-
ABNT
STEFANO, Jose Tadeu et al. Non-pharmacological management options for MAFLD: a practical guide. Therapeutic advances in endocrinology and metabolism, v. 14, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/52946. Acesso em: 06 out. 2024. -
APA
Stefano, J. T., Duarte, S. M. B., Altikes, R. G. R. L., & Oliveira, C. P. M. S. de. (2023). Non-pharmacological management options for MAFLD: a practical guide. Therapeutic advances in endocrinology and metabolism, 14. doi:10.1177/20420188231160394 -
NLM
Stefano JT, Duarte SMB, Altikes RGRL, Oliveira CPMS de. Non-pharmacological management options for MAFLD: a practical guide [Internet]. Therapeutic advances in endocrinology and metabolism. 2023 ; 14[citado 2024 out. 06 ] Available from: https://observatorio.fm.usp.br/handle/OPI/52946 -
Vancouver
Stefano JT, Duarte SMB, Altikes RGRL, Oliveira CPMS de. Non-pharmacological management options for MAFLD: a practical guide [Internet]. Therapeutic advances in endocrinology and metabolism. 2023 ; 14[citado 2024 out. 06 ] Available from: https://observatorio.fm.usp.br/handle/OPI/52946 - Should PNPLA3 polymorphism be performed in clinical practice in patients with NAFLD to predict the risk of disease progression?
- Liver transplantation in Latin America: reality and challenges
- Impact of Endoscopic Sleeve Gastroplasty in Non-alcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis
- Ultrasound elastography in patients with fatty liver disease
- Efeito do s-nitroso-n-acetilcisteína (Snac) na fibrogênese hepática em modelo experimental de doença hepática gordurosa não alcoólica (DHGNA)
- Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
- Gut Dysbiosis and Increased Intestinal Permeability Drive microRNAs, NLRP-3 Inflammasome and Liver Fibrosis in a Nutritional Model of Non-Alcoholic Steatohepatitis in Adult Male Sprague Dawley Rats
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- Potential beneficial effect of rifaximin in the prevention of hepatocellular carcinoma through the modulation of the microbiota in an experimental model of non-alcoholic fatty liver disease
- Esteato-hepatite não alcoólica
Informações sobre o DOI: 10.1177/20420188231160394 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas